Form 4: CalciMedica CFO Stephen Bardin Buys 1,000 Shares of Company Stock

CalciMedica, Inc.'s Chief Financial Officer, Stephen Bardin, acquired 1,000 shares of common stock at $1.69 per share, increasing his direct beneficial ownership to 41,000 shares.

Summary

• Stephen Bardin, Chief Financial Officer of CalciMedica, Inc. (CALC), purchased 1,000 shares of the company's common stock.
• The transaction occurred on May 30, 2025, at a price of $1.69 per share.
• Following this acquisition, Mr. Bardin directly beneficially owns a total of 41,000 shares of CalciMedica common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The insider purchase by the CFO is a positive signal of confidence, though the transaction size is relatively small and was pre-planned under a 10b5-1 plan, which slightly tempers the immediate market timing signal.

Positives

• An insider purchase by the Chief Financial Officer can signal management's confidence in the company's future prospects and valuation.
• The acquisition increases the CFO's direct stake in the company, aligning his interests more closely with those of shareholders.

Negatives

• The transaction volume of 1,000 shares is relatively small, which might limit its perceived significance.
• The purchase was made under a Rule 10b5-1 plan, which means the decision to buy was made in advance, potentially reducing the immediate signal of market timing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider purchases, especially by key executives like the CFO, are generally viewed positively across all industries as they indicate management's belief in the company's value and future performance. For a biotechnology company like CalciMedica, such a purchase might signal confidence in ongoing clinical trials, regulatory approvals, or commercialization efforts, although this specific filing does not provide details on the underlying reasons.

Comparison to Industry Standards

• This Form 4 filing reports a standard insider transaction and does not provide data points that allow for direct comparison to industry-specific financial or operational benchmarks. The significance of the transaction is primarily in the signal of insider confidence rather than a performance metric.

Related Party Transactions

• The reported transaction is an acquisition of common stock by Stephen Bardin, the Chief Financial Officer of CalciMedica, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.

Next Steps

• The document does not specify any future actions, events, or milestones related to the company's operations or strategy, as it is solely focused on reporting an insider stock transaction.

Key Dates

Recommendation

Keywords

CalciMedica, CALC, Stephen Bardin, CFO, Insider Trading, Stock Purchase, Form 4, SEC Filing, Biotechnology, Pharmaceuticals, Equity Acquisition